Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 2Leukemia 2Unspecified Childhood Solid Tumor, Protocol Specific 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Sarcoma, Ewing 1Pinealoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic NUT Carcinoma 1Medulloblastoma 1Lymphoma, Primary Effusion 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Lung Neoplasms 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Endodermal Sinus Tumor 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Embryonal 1

Interventions

molibresib 1etoposide phosphate 1Platinum 1Etoposide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic NUT Carcinoma × etoposide phosphate × Clear all
NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡